Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitotic kinesin-like protein 1 (MKLP1, also known as KIF23 or CHO1) is a plus end–directed microtubule-dependent motor protein and a key component of the centralspindlin complex, required for cytokinesis in animal cells[4][7][8]. MKLP1 cross-bridges antiparallel microtubules of the central spindle during anaphase and becomes concentrated in the midbody during cytokinesis, where it drives the formation of the cleavage furrow and completion of cell division[7][8][9]. In neurons, MKLP1 contributes to the regulation of microtubule transport and dendrite formation[7]. Dysfunction or overexpression of MKLP1 has been linked to cancer and possibly hereditary cell division disorders[8][9]. As it is essential in rapidly dividing cells, MKLP1 is regarded as a potential anti-cancer drug target[8].
Inhibition of motor activity: Drugs targeting MKLP1/KIF23 would be expected to block its ATPase/microtubule-interacting functions, leading to failed cytokinesis and cancer cell death. Disruption of spindle assembly and furrow ingression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitotic kinesin-like protein 1 (MKLP1).